Triple-negative breast cancer--current status and future directions.
暂无分享,去创建一个
N Harbeck | L. Pusztai | N. Harbeck | O. Gluz | C. Liedtke | U. Nitz | L Pusztai | U Nitz | C Liedtke | O Gluz | N Gottschalk | N. Gottschalk
[1] S. Verma,et al. Platinum-based chemotherapy in triple-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[3] L. Pusztai,et al. Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Winer,et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Winer,et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Lubiński,et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Narod,et al. Time to disease recurrence in basal‐type breast cancers , 2009, Cancer.
[8] J. Jassem,et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2009, European journal of cancer.
[9] S. O'toole,et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Klijn,et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Wei Zhou,et al. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.
[12] A. Richardson,et al. Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers , 2009, The American journal of surgical pathology.
[13] M. Rinaldo,et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] C. Sotiriou,et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Patt,et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Tutt,et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Christine B Ambrosone,et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors , 2009, Breast Cancer Research.
[18] T. Shibata,et al. Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Pusztai,et al. A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients. , 2009, Journal of Clinical Oncology.
[20] A. Niwińska,et al. The role of systemic treatment after whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases: Differences depending on biological subtype. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Pegram,et al. Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. André,et al. Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: A tissue microarray. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Denkert,et al. Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Maiti,et al. The association of metabolic syndrome with triple-negative breast cancer , 2010, Breast Cancer Research and Treatment.
[25] S Badve,et al. Genotypic characterization of phenotypically defined triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Melnick,et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.
[27] M. Clynes,et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] R. Coates,et al. The epidemiology of triple-negative breast cancer, including race , 2009, Cancer Causes & Control.
[29] D. Noh,et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] I. Ellis,et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.
[31] L. Brinton,et al. Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years , 2009, Cancer Epidemiology Biomarkers & Prevention.
[32] J. Ahn,et al. Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy , 2009, International journal of cancer.
[33] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] T. Uematsu,et al. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. , 2009, Radiology.
[36] Tianyu Li,et al. Locoregional recurrence of triple‐negative breast cancer after breast‐conserving surgery and radiation , 2009, Cancer.
[37] Winfried Brenner,et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Karen R. Sepucha,et al. Can women with early-stage breast cancer make an informed decision for mastectomy? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Dering,et al. Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents. , 2009 .
[40] R. Gray,et al. GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. , 2009 .
[41] M. Fernö,et al. Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer. , 2009 .
[42] M. Fernö,et al. Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer , 2009 .
[43] A. Makris,et al. BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer. , 2009 .
[44] N. Ibrahim,et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. , 2009 .
[45] C. Desmedt,et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. , 2009 .
[46] F. Esteva,et al. Survival among women with triple receptor-negative breast cancer and brain metastases. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] T. Nielsen,et al. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] C. Perou,et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] B. Kreike,et al. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis , 2009, Breast Cancer Research and Treatment.
[50] E. Sağlam,et al. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis , 2009, Journal of Neuro-Oncology.
[51] S. Narod,et al. Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[52] T. Lash,et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.
[53] Stephanie A Cohen,et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.
[54] S. Narod,et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers , 2009, Breast Cancer Research and Treatment.
[55] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[56] N. Lin,et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.
[57] P. Borst,et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.
[58] H. Kaplan,et al. Impact of Triple Negative Phenotype on Breast Cancer Prognosis , 2008, The breast journal.
[59] Daniel Birnbaum,et al. How basal are triple‐negative breast cancers? , 2008, International journal of cancer.
[60] F. Penault-Llorca,et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] M. Ringnér,et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.
[62] J. Henson,et al. Survival in patients with brain metastases from breast cancer , 2008, Cancer.
[63] C. Perou,et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .
[64] F. Heitz,et al. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors , 2008 .
[65] T. Whelan,et al. Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial , 2008 .
[66] S. Johnston,et al. Platinum-based chemotherapy in triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] Barbara L. Smith,et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] N. Harbeck,et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[70] E. Perez,et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.
[71] H. Rugo,et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] H. Nevanlinna,et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer , 2008, Oncogene.
[73] F. B. Sørensen,et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[76] A. Alavi,et al. Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters , 2008, Cancer.
[77] Gema Moreno-Bueno,et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.
[78] A. Tsodikov,et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004 , 2008, Cancer.
[79] M. Sormani,et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.
[80] Lisa A. Carey,et al. Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose-Dense Chemotherapy , 2008 .
[81] S. Küçücük,et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] G. Hortobagyi,et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women , 2008, Breast Cancer Research and Treatment.
[83] A. Rademaker,et al. αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.
[84] Robin L. Jones,et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.
[85] A. Luini,et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel , 2008, Cancer Chemotherapy and Pharmacology.
[86] C. Perou,et al. Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.
[87] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[88] Daniel Birnbaum,et al. Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.
[89] O. Nalcioglu,et al. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] Robert N Hoover,et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.
[91] M. García-Closas,et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. , 2007, Cancer research.
[92] Larry Norton,et al. HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.
[93] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] A. Rosenberg,et al. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.
[95] Simone Schrading,et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study , 2007, The Lancet.
[96] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[97] Marc Tischkowitz,et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.
[98] Jos Jonkers,et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.
[99] R. Gelber,et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[100] J. Hainsworth,et al. A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer , 2007 .
[101] E. Álava,et al. Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): Relevance of HER2 and hormonal status (HR) , 2007 .
[102] T. Petit,et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers? , 2007 .
[103] D. Sgroi,et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. , 2007, The Journal of clinical investigation.
[104] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[105] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[106] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] A. Ashworth,et al. BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.
[108] Wolfgang Heller,et al. Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.
[109] M. García-Closas,et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.
[110] Fei Huang,et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.
[111] Arndt Hartmann,et al. Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy , 2007, Clinical Cancer Research.
[112] J. O’Shaughnessy,et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer , 2007 .
[113] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[114] J. Dering,et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.
[115] J. Weidhaas,et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] Donald Berry,et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 , 2006, Breast Cancer Research.
[117] Robert Tibshirani,et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.
[118] S. Lakhani,et al. Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.
[119] D. Easton,et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.
[120] S. Schnitt,et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] F. Penault-Llorca,et al. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] O. Gluz,et al. Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: A hypothesis generating study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[124] H. Harputluoglu,et al. Albumin-Bound Paclitaxel, ABI-007 May Show Better Efficacy than Paclitaxel in Basal-Like Breast Cancers: Association Between Caveolin-1 Expression and ABI-007 , 2006, Breast Cancer Research and Treatment.
[125] M. Privat,et al. BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel Resistance , 2006, Cell cycle.
[126] A. Ashworth,et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.
[127] J. Benítez,et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.
[128] J. Benítez,et al. Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.
[129] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[130] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[131] François Vaillant,et al. Generation of a functional mammary gland from a single stem cell , 2006, Nature.
[132] D. Birnbaum,et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.
[133] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[134] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[135] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[136] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[137] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[138] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[139] W. Foulkes,et al. A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors , 2005, Cancer Epidemiology Biomarkers & Prevention.
[140] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[141] I. Bedrosian. The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer , 2005 .
[142] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[143] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[144] E. Liu,et al. BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3 , 2004, Cancer Research.
[145] C. Perou,et al. Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.
[146] L. Bégin,et al. The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.
[147] Sridhar Ramaswamy,et al. Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers , 2004, Cancer Research.
[148] A. Hutcheon,et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.
[149] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[150] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[151] Martin Eisenacher,et al. Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.
[152] P. Chappuis,et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.
[153] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[154] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[155] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[156] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[157] E. Ernst. Mistletoe for cancer? , 2001, European journal of cancer.
[158] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[159] S. Hirohashi,et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. , 2000, The American journal of surgical pathology.
[160] S. Hirohashi,et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. , 1999, Human pathology.
[161] J. Peto,et al. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours , 1998, Oncogene.
[162] J Isola,et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.
[163] J. Glenney. The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles , 1992, FEBS letters.
[164] L. Puett,et al. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. , 1988, Journal of the National Cancer Institute.